Switzerland's Obseva eyes China re-start for fertility drug that failed trial

ObsEva struck a pact with China's Yuyuan BioScience Technology to develop and commercialize the fertility drug nolasiban, the Swiss drugmaker said on Monday as it seeks to inject new life into a medicine that had flopped a trial.

from Reuters: Health News https://ift.tt/3a7zLkn
via IFTTT